Cargando…

Comparison of the prognostic values of three calculation methods for echocardiographic relative wall thickness in acute decompensated heart failure

PURPOSE: Left ventricular (LV) wall thickness can be measured at the posterior wall (PW) and the intraventricular septum (IVS) in a parasternal long axis view by transthoracic echocardiography. Thus, there are three methods to calculate relative wall thickness as follows: RWT(PW) = 2 × PWth/LVDd; RW...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamaguchi, Satoshi, Shimabukuro, Michio, Abe, Masami, Arakaki, Tomohiro, Arasaki, Osamu, Ueda, Shinichiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6891973/ https://www.ncbi.nlm.nih.gov/pubmed/31796050 http://dx.doi.org/10.1186/s12947-019-0179-6

Ejemplares similares

Prognostic Impact of Early Changes in Serum Chloride Concentrations Among Hospitalized Acute Heart Failure Patients　― A Retrospective Cohort Study ―
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial
por: Ueda, Shinichiro, et al.
Publicado: (2018)

Age-Dependent Efficacy of Ezetimibe for Low-Density Lipoprotein Cholesterol Reduction in Japanese Patients with or without Type 2 Diabetes Mellitus
por: Yamaguchi, Satoshi, et al.
Publicado: (2020)

Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2020)

Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
por: Teragawa, Hiroki, et al.
Publicado: (2022)

Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2019)

Author Correction: Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial
por: Morimoto, Takeshi, et al.
Publicado: (2020)

Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial
por: Chihara, Atsuko, et al.
Publicado: (2019)

Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial
por: Hirai, Hiroyuki, et al.
Publicado: (2019)

Prognostic Value of the Echocardiographic Probability of Pulmonary Hypertension in Patients with Acute Decompensated Heart Failure
por: Carballo, Sebastian, et al.
Publicado: (2019)

Echocardiographic predictors of change in renal function with intravenous diuresis for decompensated heart failure
por: Gannon, Stephen A., et al.
Publicado: (2018)

Clinical and Echocardiographic Findings of Newly Diagnosed Acute Decompensated Heart Failure in Elderly Patients
por: Moon, Jeonggeun, et al.
Publicado: (2011)

Fibrin glue patch for pacemaker lead perforation of the right ventricular free wall: A case report
por: Yamaguchi, Satoshi, et al.
Publicado: (2015)

Eicosapentaenoic Acid Supplementation Changes Fatty Acid Composition and Corrects Endothelial Dysfunction in Hyperlipidemic Patients
por: Yamakawa, Ken, et al.
Publicado: (2012)

Serial Electrocardiographic Changes in Early Post-myocardial Infarction Pericarditis
por: Hirata, Kazuhito, et al.
Publicado: (2022)

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus
por: Furuhashi, Masato, et al.
Publicado: (2020)

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy
por: Furuhashi, Masato, et al.
Publicado: (2020)

Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy
por: Furuhashi, Masato, et al.
Publicado: (2022)

Prognostic Effect of a Novel Simply Calculated Nutritional Index in Acute Decompensated Heart Failure
por: Ishiwata, Sayaki, et al.
Publicado: (2020)

Women with type 2 diabetes and coronary artery disease have a higher risk of heart failure than men, with a significant gender interaction between heart failure risk and risk factor management: a retrospective registry study
por: Fujita, Yuko, et al.
Publicado: (2022)

Prognostic Value of Calculated Plasma Volume Status in Patients Admitted for Acute Decompensated Heart Failure　― A Prospective Comparative Study With Other Indices of Plasma Volume ―
por: Tamaki, Shunsuke, et al.
Publicado: (2019)

Echocardiographic hemodynamic assessment in decompensated cirrhosis: comparison between Intensivists and Gastroenterologists
por: Prost, Ardavan, et al.
Publicado: (2023)

Acute Myocardial Infarction During the Last Part of a Triathlon: A Case Report
por: Yamaguchi, Satoshi, et al.
Publicado: (2022)

Intestinal cholesterol embolism resulting from intra-aortic balloon pumping: a case report
por: Yamaguchi, Satoshi, et al.
Publicado: (2014)

Echocardiographic Epicardial Adipose Tissue Thickness for Risk Stratification of Patients With Heart Failure
por: Parisi, Valentina, et al.
Publicado: (2020)

Decompensated heart failure
por: Mangini, Sandrigo, et al.
Publicado: (2013)

The Usefulness of Prioritization of Ivabradine Before Beta-Blockers in a Heart Failure Patient Suffering From Intra-hemodialysis Hypotension
por: Yamaguchi, Satoshi, et al.
Publicado: (2023)

Impact of individual metabolic risk components or its clustering on endothelial and smooth muscle cell function in men
por: Shimabukuro, Michio, et al.
Publicado: (2016)

Iatrogenic Decompensated Heart Failure
por: Tran, Patrick, et al.
Publicado: (2020)

Effectiveness of continuous low‐dose fasudil on refractory coronary vasospasm subsequent to cardiopulmonary arrest
por: Ooshiro, Daisuke, et al.
Publicado: (2017)

Prognostic Value of Fractional Excretion of Urea Nitrogen at Discharge in Acute Decompensated Heart Failure
por: Nogi, Kazutaka, et al.
Publicado: (2021)

The Relationship between Angiotensin–Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure
por: Zhang, Xiaoliang, et al.
Publicado: (2022)

Effect of carperitide on the 1 year prognosis of patients with acute decompensated heart failure
por: Nogi, Kazutaka, et al.
Publicado: (2022)

Acute Decompensated Heart Failure Update
por: Teerlink, John R, et al.
Publicado: (2015)

Multimodality imaging in decompensated heart failure
por: D’Andrea, Antonello, et al.
Publicado: (2023)

Clinical implication of initial intravenous diuretic dose for acute decompensated heart failure
por: Yoshioka, Kenji, et al.
Publicado: (2022)

Subclinical hypothyroidism is an independent predictor of adverse cardiovascular outcomes in patients with acute decompensated heart failure
por: Hayashi, Tomohiro, et al.
Publicado: (2016)

Trajectories of Left Ventricular Ejection Fraction After Acute Decompensation for Systolic Heart Failure: Concomitant Echocardiographic and Systemic Changes, Predictors, and Impact on Clinical Outcomes
por: Albert, Judith, et al.
Publicado: (2021)

Prognostic impact of nutritional status and physical capacity in elderly patients with acute decompensated heart failure
por: Yasumura, Kaori, et al.
Publicado: (2020)

Impact of Atrial Fibrillation on the Prognosis of Acute Decompensated Heart Failure With and Without Mitral Regurgitation
por: Hirai, Kaeko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_81genc4uplvjfcijktv56mi3f2